Skip to main content

Want a detailed portfolio tracker?

Performance analysis of Nuvectis Pharma (NVCT)

Annual Return

Over the past 3 years, NVCT has had an average annual return of +8.32%, underperforming the benchmark SPY, which returned +19.63% annual.

Since Feb 4, 2022, NVCT has had an average annual return of +48.71%, outperforming the benchmark SPY, which returned +13.70% annual.

20262025202420232022
+152.71%+39.56%-35.13%+11.20%+130.77%

Monthly Return

YearJanFebMarAprMayJunJulAugSepOctNovDecAnnually Total
2026+7.42%+9.25%-12.75%+10.73%+13.90%+88.62%+3.75%+152.71%
2025+24.95%-1.03%+46.04%+1.94%-5.52%-20.62%-6.83%-5.74%-8.23%+11.46%-7.00%+20.99%+39.56%
2024-12.59%+35.39%-16.92%-25.85%+11.35%-6.50%+0.31%+9.61%-9.62%+18.76%-32.53%+7.34%-35.13%
2023+32.27%+15.22%+14.70%+12.89%+18.24%-8.74%-12.02%+1.85%-9.92%-30.57%-5.03%-1.88%+11.20%
2022+111.38%+7.86%+28.21%+58.21%-25.48%-21.43%-7.96%-12.47%-4.37%+8.40%+2.04%+130.77%

Drawdown analysis of Nuvectis Pharma (NVCT)

The maximum drawdown for the NVCT was -77.89%, occurring on Dec 20, 2024. Recovery took 375 trading sessions.

The current NVCT drawdown is -33.12%.

Since Feb 4, 2022 NVCT has experienced the following drawdowns:

  • 50% or more: 1 time
  • 40% or more: 1 time
  • 30% or more: 4 times
  • 20% or more: 5 times
  • 10% or more: 6 times
DepthStartTo BottomBottomTo RecoverEndTotal
-77.89%May 17, 2022653Dec 20, 2024375Jun 24, 20261028
-36.80%Jun 29, 202614Jul 20, 2026OngoingOngoingOngoing
-33.74%Mar 14, 20225Mar 21, 202212Apr 6, 202217
-31.95%Feb 7, 20225Feb 14, 202215Mar 8, 202220
-21.87%May 6, 20222May 10, 20223May 13, 20225
-11.80%Apr 6, 202215Apr 28, 20223May 3, 202218
-2.44%Jun 25, 20261Jun 26, 20261Jun 29, 20262
-1.90%Mar 9, 20221Mar 10, 20222Mar 14, 20223
-0.52%May 3, 20221May 4, 20221May 5, 20222